MDSFD-Net:通过解学习和特征蒸,通过缺失模式诊断阿尔茨海默病
Nana Jia1, Zhiao Zhang1, Tong Jia2
1College of Information Science and Engineering, Northeastern University, Shenyang, 504874, Liaoning, China.
概括
这项研究引入了使用不完整的多模式数据诊断阿尔茨海默病 (AD) 的新网络. 该MDSFD-Net有效地归咎于缺失的数据,并提炼了准确早期诊断的关键特征.
科学领域:
- 神经成像和计算神经科学
- 医疗保健中的人工智能
- 生物医学数据分析
背景情况:
- 多模式分析对于早期阿尔茨海默病 (AD) 诊断至关重要.
- 缺失的数据模式对现有的诊断方法构成重大挑战.
- 目前缺少数据的生成模型经常忽视模式特定的特征,导致偏见的预测.
研究的目的:
- 开发一个新的网络,MDSFD-Net,用于在缺失模式的情况下诊断AD.
- 通过有效利用可用数据的共同和特定特征来解决现有方法的局限性.
- 在没有完整的多模式数据的情况下,提高AD诊断的准确性和稳定性.
主要方法:
- 提出了模式解和特征蒸网络 (MDSFD-Net) 的建议.
- 实现了一个基于解的归算 (DI) 模块,使用空间通道模式解学习方案.
- 整合了特定特征蒸 (SFD) 模块与规范化知识蒸 (R-KD) 以将知识从完整模式转移到不完整模式.
主要成果:
- 该DI模块有效地解开模式特定和共享的特征用于归算.
- SFD模块成功地将基本的特定特征从完整的模式转移到不完整的模式.
- 在缺失模式场景中,MDSFD-Net在ADNI数据集上表现优于最先进的方法.
结论:
- MDSFD-Net有效地处理多模式AD诊断中缺失的模式.
- 拟议的方法利用假定共享特征和蒸特征来进行稳健的分类.
- 这种方法在没有完整数据的情况下,为早期AD诊断提供了一个有希望的解决方案.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
33.7K
06:48Lexical Decision Task for Studying Written Word Recognition in Adults with and without Dementia or Mild Cognitive Impairment
Published on: June 25, 2019
9.7K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
